|
|
|
|
|
|
|
|
|
|
September 26, 2006 — The US Food and Drug Administration (FDA) and
> Genentech, Inc, have notified healthcare professionals regarding
> safety labeling revisions for bevacizumab injection (Avastin) that
> warn of potential risks for reversible posterior leukoencephalopathy
> syndrome (RPLS) and nasal septum perforation associated with its use.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.